Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.46 USD
-0.03 (-5.33%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.45 -0.01 (-1.51%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Sangamo Therapeutics, Inc. has a market cap of $112.53M, which represents its share price of $0.48 multiplied by its outstanding shares number of 233.17M. As a small-cap company, SGMO's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SGMO 0.46 -0.03(-5.33%)
Will SGMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for SGMO
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ...
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Sangamo Therapeutics GAAP EPS of -$0.08 misses by $0.04, revenue of $18.3M misses by $13.38M